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SRIDEVI DEVARAJ, PHD3
OBJECTIVEdThe metabolic syndrome (MetS) is highly prevalent and confers an increased
risk for diabetes and cardiovascular disease (CVD). While MetS is a proinflammatory state, there
is a paucity of data on cellular inflammation in MetS. Toll-like receptors (TLRs) are classical
pattern recognition receptors of the innate immune response.
RESEARCH DESIGN ANDMETHODSdThe aim of this study was to examine mono-
cyte TLR2 and TLR4 inMetS patients without diabetes or CVD and control subjects since both of
the receptors have been implicated in atherosclerosis and insulin resistance. Fasting blood was
obtained for TLR expression and activity.
RESULTSdCirculating levels of high-sensitivity C-reactive protein, interleukin (IL)-1b, IL-6,
IL-8, and soluble tumor necrosis factor receptor 1 (sTNFR1) were significantly increased in MetS
versus control subjects following adjustment for waist circumference. There was a significant
increase in both TLR2 and TLR4 surface expression and mRNA on monocytes after adjustment
for waist circumference. In addition to increased nuclear factor-kB nuclear binding, there was
significantly increased release of IL-1b, IL-6, and IL-8 in MetS versus control subjects following
priming of the monocytes with lipopolysaccharides. While both plasma free fatty acids and
endotoxin were increased in MetS, they correlated significantly with TLR4 only.
CONCLUSIONSdIn conclusion, we make the novel observation that both TLR2 and TLR4
expression and activity are increased in the monocytes of patients with MetS and could contrib-
ute to increased risk for diabetes and CVD.
Diabetes Care 35:900–904, 2012
Metabolic syndrome (MetS) affectsone in three U.S. adults and con-fers an increased risk for both di-
abetes and cardiovascular disease (CVD)
(1,2). It is clearly becoming apparent that,
in addition to the diagnostic criteria used
for MetS by the National Cholesterol Edu-
cation Program Adult Treatment Panel III
(NCEP ATP III), both insulin resistance
and low-grade inflammation, as docu-
mented by circulating biomarkers, are
also evident (3–5). However, with regards
to the low-grade inflammation, there is a
paucity of data with regards to the cellu-
lar basis for the proinflammatory pheno-
type of MetS uncomplicated by diabetes
and/or CVD (6). Recently, we showed
that subcutaneous adipose tissue of na-
scent MetS patients without diabetes or
CVD produced increased levels of adipo-
kines compared with matched control
subjects, and they correlated with both
the proinflammatory state and the insulin
resistance of these patients (6). However, the
sentinel cell of inflammation and innate im-
munity is the monocyte/macrophage. There
is scanty data on monocyte function in pa-
tients with MetS. Natal et al. (7) showed in-
creased monocyte CD40L/CD40 expression
inMetS but did not report on downstream
signaling or biomediators of this dyad. In
this study, we provide further evidence
for the proinflammatory state of MetS by
studying the classical pathogen recognition
receptors of the innate immune response,
Toll-like receptors (TLRs). The TLRs that
we studied included TLR2 and TLR4 since
both of the receptors have been incrimi-
nated in both atherosclerosis and insulin
resistance (8–13).
RESEARCH DESIGN AND
METHODS
Patients and methods
All subjects were recruited from Sacra-
mento County, California, through fliers
and advertisements in the newspaper. The
subjects (aged 21–70 years) with MetS (n =
49) and healthy control subjects (n = 41)
were studied. MetS was defined using the
criteria of the NCEP ATP III (1,2). Briefly,
subjects classified as MetS must have at
least three risk factors to sustain the diag-
nosis, including central obesity, hyper-
tension, dyslipidemia (low HDL, high
triglycerides), and/or hypertension on anti-
hypertensivemedications. Control subjects
needed to have#2 features of MetS and not
be on blood pressure medications. Other
exclusion criteria for control subjects were
fasting plasma glucose (.100 mg/dL) and
triglycerides (TGs) (.200 mg/dL) (14).
Other exclusion criteria for both
groups were diabetes, clinical atheroscle-
rosis (coronary artery disease, peripheral
arterial disease, CVD, etc.), smoking,
hypo- or hyperthyroidism, malabsorp-
tion, anticoagulant therapy, steroid ther-
apy, anti-inflammatory drugs, statin and
other hypolipidemic therapy, hypoglyce-
mic agents, angiotensin receptor blockers,
TG .400 mg/dL (for MetS subjects), oral
contraceptives, use of antioxidant supple-
ments in the past 6 months, pregnancy,
abnormal complete blood count, alcohol
consumption.1 oz/day, consumption of
n-3 polyunsaturated fatty acid, postmen-
opausal women on estrogen replacement
therapy, active wounds, recent surgery, in-
flammatory ormalignant disease,C-reactive
protein (CRP) .10 mg/L, and chronic
high-intensity exercisers (exercise .100
min/week). Diabetes was excluded by
two fasting glucose levels (screening and
day of monocyte isolation) ,126 mg/dL
and an HbA1c ,6.5%.
Informed consent was obtained from
participants in the study, which was ap-
proved by the institutional review board
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at the University of California Davis. All
human investigation was conducted accord-
ing to the principles expressed in the Decla-
ration of Helsinki. After history and physical
examination, fasting blood was obtained.
A complete blood count, plasma lipid and
lipoprotein profile, urea nitrogen, creatinine,
aspartate aminotransferase, alanine amino-
transferase, glucose, and thyrotropin were
assayed by standard laboratory techniques
in the Clinical Pathology Laboratory. Insu-
lin levels were assayed by enzyme-linked
immunosorbent assay (Linco Biosystems),
and homeostasis model assessment of in-
sulin resistance (HOMA-IR) was calculated
from glucose and insulin levels as previ-
ously described (14–16).
After subjects were screened, if theymet
the selection criteria, they were requested
to come to the University of California
Davis Clinical and Translational Science
Center Clinical Research Center for a fast-
ing blood draw. Plasma free fatty acid
(FFA) levels were assayed as previously
described (16), and endotoxin levels were
quantitated using reagents from Lonza
(Limulus Amebocyte Lysate, QCL 1000;
Walkersville, MD).
Levels of soluble tumor necrosis factor
receptor 1 (sTNFR1) and 2 (sTNFR2) were
assayed using a quantitative sandwich
enzyme immunoassay technique using
monoclonal antibodies to sTNFR1 and 2,
respectively (R&D Biosystems, MN). All the
above assays were performed in duplicate.
Monocyte isolation
Mononuclear cells were isolated from fast-
ing heparinized blood by Ficoll Hypaque
centrifugation followed by magnetic sep-
aration using the depletion technique
(Miltenyi Biotech, Auburn, CA) as previ-
ously described (15). Using this technique,
more than 92% of cells were identified as
monocytes by CD14 staining. Isolated
monocytes were studied before and after
activation with lipopolysaccharides (LPS)
(from Escherichia coli 026:B6, 100 ng/mL;
Sigma Chemicals, St. Louis, MO). Super-
natants were collected after an overnight
incubation for assessment of cytokines/
chemokines by multiplex immunoassays
as previously described (15,16).
Surface expression of TLR2
and TLR4
Monocytes from control and MetS sub-
jects were incubated with anti-human
TLR2 and TLR4 antibodies (InvivoGen)
or isotype controls, and surface expres-
sion of TLR2 and TLR4 were analyzed
using BD FACSArray (Franklin Lakes,
NJ) after gating for CD14 as previously
described (15,16). Results were expressed
as mean fluorescence intensity of 10,000
cells. Intra-assay and interassay coefficient
of variation for TLR2 and TLR4 expression
was ,5% and ,15%, respectively.
TLR2 and TLR4 mRNA expression
RNA was isolated from the monocytes
using TRIzol reagent (Invitrogen, Carlsbad,
CA). RT-PCR was performed using TLR2,
TLR4, and 18sRNAprimers (Invivogen, San
Diego, CA) following the manufacturer’s
cycling parameters. Band intensities were
determined using Image Quant Software
(GE Healthcare Biosciences, Piscataway,
NJ) as previously described (15) and ex-
pressed as ratio of TLR mRNA/18s RNA.
Cell signaling studies
Monocyte nuclear extracts were prepared
as previously described (15,16), and nu-
clear factor (NF)-kB p65 activity in the nu-
clear extracts were assessed using reagents
from Bio-Rad using the Bioplex multiplex
assays following the manufacturer’s in-
structions. The intra-assay coefficients of
variations of the assays were,14%.
Statistical analysis
Data are expressed as mean 6 SD or, for
skewed variables, as median and inter-
quartile range. Log transformations were
applied to skewed data prior to parametric
analyses. Comparisons between the control
and MetS groups were made with two-
sample t tests. Spearman rank correlation
coefficients were computed to assess the
association between metabolic risk factors
and monocyte activity. Multiple regression
models were constructed to evaluate predic-
tors ofmonocyte-dependent variables. Inde-
pendent variables assessed included age,
BMI, waist circumference, blood pressure,
plasma glucose, TGs, HOMA-IR, LDL cho-
lesterol, HDL cholesterol, and CRP, FFA,
and endotoxin. Data were analyzed using
SAS version 9.1.3 (SAS Institute, Cary, NC).
RESULTSdTable 1 shows salient char-
acteristics of the studied population. In
addition to the features of MetS, which
are significantly abnormal in the patients
with MetS, it is important to appreciate
that both high-sensitivity CRP (hs-CRP)
levels and HOMA-IR are also increased.
Also circulating levels of IL-1b, IL-6, and
IL-8 and sTNFR1 levels were significantly in-
creased in MetS versus control subjects even
following adjustment for waist circumfer-
ence. However, both TNF and monocyte
chemoattractant protein (MCP)-1 levels
were similar, and there was a trend to sig-
nificance in sTNFR2 (P = 0.08, following
waist circumference adjustment).
Table 1dBaseline characteristics
Control subjects MetS
n 41 49
Age (years) 48 6 12 51 6 10
Waist circumference (cm) 92 6 15 107 6 12*
BMI (kg/m2) 30.4 6 6.6 34.7 6 6.6*
BP-systolic (mmHg) 117 6 13 131 6 11*
BP-diastolic (mmHg) 73 6 8 82 6 9
Glucose (mg/dL) 88 6 7 100 6 11*
Total cholesterol (mg/dL) 189 6 32 201 6 28
Total triglycerides (mg/dL) 72 (60–97) 151 (104–174)*
HDL cholesterol (mg/dL) 54 6 15 41 6 11*
LDL cholesterol (mg/dL) 118 6 26 130 6 21
hsCRP (mg/dL) 1.3 (0.5–2.8) 3.7 (1.7–5.6)*
HOMA-IR 1.1 (0.9–2.8) 2.4 (1.8–5.8)*
Plasma FFAs (mmol/L) 0.34 6 0.18 0.81 6 0.18**
Plasma endotoxin (EU/mL) 3.86 6 0.59 12.95 6 2.97**
Plasma sTNFR1 (pg/mL) 933 6 248 1,220 6 303*
Plasma sTNFR2 (pg/mL) 2,037 6 546 2,496 6 719
Plasma IL-8 (pg/mL) 2.3 (0.4–6.6) 4.9 (0.9–8.9)*
Plasma MCP-1 (pg/mL) 4.2 (0.4–7.5) 5.7 (1.0–9.1)
Plasma IL-1b (pg/mL) 7.3 (2.4–10.5) 15.7 (3.3–29.1)*
Plasma TNF (pg/mL) 345 (248–468) 287 (249–575)
Plasma IL-6 (pg/mL) 875 (389–1,425) 1,799 (1,396–2,145)***
Data are mean6 SD or median (interquartile range). BP, blood pressure. *P, 0.05 compared with control
subjects. **P , 0.001 compared with control subjects. ***P , 0.0001 compared with control subjects.
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With regard to monocyte biology,
Fig. 1A depicts TLR2 and TLR4 levels
quantitated by flow cytometry. There
was a significant increase in both TLR2
and TLR4 in MetS that persisted after ad-
justment for waist circumference (Fig. 1)
and also BMI (data not shown). In a sub-
group we showed increased TLR2 and
TLR4 mRNA expression on monocytes in
MetS compared with control subjects (Fig.
1B). A pivotal downstream readout of the ac-
tivated TLR2 and TLR4 pathways is NF-kB,
cytokines, and chemokines. As shown in
Fig. 2, there is increased nuclear NF-kB
binding inMetS (P,0.001). Figure 3 shows
significant increases in IL-1b, IL-6, and IL-8
in MetS versus control subjects following
priming of themonocytes with the classical
TLR4 agonist, LPS (P , 0.05). However
with regard to MCP-1 and TNF-a, the dif-
ferences between the two groups were not
significant (MCP-1: controls 156 [129–
998] vs. MetS 432 [171–895] pg/mL;
TNF: controls 345 [248–468] vs. MetS
287 [250–583] pg/mL; data presented as
median and interquartile range, P. 0.05).
We correlated features of MetS with
TLR2 and TLR4. TLR2 correlated signif-
icantly with waist circumference (r = 0.22,
P , 0.05) and blood pressure (r = 0.32,
P = 0.002). TLR4 correlated significantly
with plasma glucose (r = 0.21, P, 0.05)
and TGs (r = 0.28, P = 0.01). TLR4 cor-
related significantly with the following:
IL-Ib (r = 0.22, P = 0.045),MCP-1 (r = 0.23,
P = 0.04), and NF-kB activity (r = 0.31,
P = 0.006). TLR2 correlated significantly
with IL-6 (r = 0.28, P = 0.02) and NF-kB
activity (r = 0.32, P = 0.006).While there
was a trend to a positive correlation be-
tween HOMA and TLR2 (r = 0.19, P =
0.08), there was a significant correlation
between TLR4 and HOMA (r = 0.26, P =
0.020).
To gain some mechanistic insights,
we assayed both FFA and endotoxin lev-
els in this clinical study. Compared with
control subjects, patients with MetS had
significantly elevated levels of both FFA
and endotoxin (P , 0.001) (Table 1).
Hence, we undertook correlations be-
tween TLR2 and TLR4 and endotoxin
and FFA. Not surprisingly, we found a sig-
nificant correlation between TLR4 and en-
dotoxin (r = 0.61, P, 0.0001), but notwith
TLR2 (r = 0.15, P = 0.37). Also, we found a
significant correlation between FFA and
TLR4, (r = 0.53, P = 0.0006), but not
with TLR2 (r = 0.12, P = 0.47).
We have previously shown a decreased
number of progenitor cells (CD34 posi-
tivity) and endothelial progenitor cells
(dual CD34 and kinase insert domain-
containing receptor [KDR] positivity) in
patients with MetS (14). As recently re-
viewed, both these cells predict cardio-
vascular events and are emerging as a
biomarker of vascular health (17). Both
TLR2 and TLR4 correlated significantly
with progenitor cell numbers (r = 20.38,
P = 0.002 and r = 20.25, P = 0.048, re-
spectively), while only TLR4 correlated sig-
nificantly with endothelial progenitor cells
(r = 20.25, P = 0.049) with a trend for
TLR2 (r = 20.23, P = 0.07).
CONCLUSIONSdMetS is a cluster of
cardiometabolic risk factors that predis-
poses to both diabetes and CVDs. Al-
though there is a large body of data on
inflammation in obesity in both animal
models and humans, not all individuals
with obesity are at a high metabolic risk,
Figure 1dA: Monocyte TLR expression. Monocytes were isolated by negative magnetic sepa-
ration, and surface expression of TLR2 and TLR4 were assessed by flow cytometry as described in
RESEARCH DESIGN AND METHODS. *P , 0.01 compared with control subjects. B: TLR2 and TLR4
mRNA expression. Representative RT-PCR gel showing significantly increased TLR2 and TLR4
mRNA expression in monocytes of MetS compared with control subjects. Densitometric values are
normalized to 18 sRNA and expressed as mean ratio6 SD (n = 7) as described in RESEARCHDESIGN
AND METHODS. *P , 0.05 compared with control subjects.
Figure 2dMonocyte signaling. Monocytes
were isolated by negative magnetic separation
and nuclear extracts for p65 of NF-kB assay
by multiplex immunoassays as described in
RESEARCH DESIGN AND METHODS. *P , 0.001
compared with control subjects.
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TLR and metabolic syndrome
and in the National Health and Nutrition
Examination Survey data, 31.7% of obese
persons appeared to have a low-risk met-
abolic phenotype (18). Hence in this
study, we decided to probe the sentinel
cell of inflammation in a high-risk obesity
state, MetS (6). In accord with our previ-
ous findings for both type 1 and type 2
diabetes (15,16), in this article we show
that patients with nascent MetS, without
the confounders of diabetes or CVD, have
increased TLR2 and TLR4 activity that
cannot be simply explained by adiposity.
This was manifest by both increased
cell surface receptor numbers, increased
mRNA levels, increase in signaling
through NF-kB activity, and increased
levels of IL-1, IL-8, IL-6 and sTNFR1.
We are unclear why MCP-1 levels are
not increased in these patients’ serum-
and LPS-primed monocytes in spite of
previously showing increased release
from subcutaneous adipose tissue (6).
While serum TNF levels were not in-
creased, there was a significant increase
in sTNFR1 and a trend to an increase in
sTNFR2. Interestingly, most of the bio-
logical functions of TNF are mediated
via TNFR1 (19). Furthermore, the sTNFRs
can bind TNF with high affinity and func-
tions as TNF antagonists. Thus, the ob-
served increase in sTNFRs could explain
the failure to detect elevated levels of TNF
since they bind to TNF.
Previous studies in animal models
have shown that knockout of both these
receptors, TLR2 and TLR4, attenuates the
progression of atherosclerosis insulin re-
sistance and diabetes (8–13). Hence the
increased activity reported here in these
patients could be advanced as a plausible
mechanism for their increased risk for di-
abetes and CVD since cellular receptor
abundance correlated with HOMA, a
measure of insulin resistance, and biome-
diators such as IL-6, IL-1, and IL-8. How-
ever, given that this is a rapidly evolving
field, we cannot conclude that either
TLR2 or TLR4 is more important in the
genesis of diabetes. With respect to dia-
betic vascular complications, Nymark
et al. (20) showed that the classical ligand
for TLR4, LPS, predicted the progression
of diabetic nephropathy. Most recently,
our group showed that compared with
wild-type, streptozotocin-induced diabe-
tes, TLR2 knockout mice attenuated the
progression of diabetic nephropathy (21).
With respect to nascent MetS, in the
only previous study that has looked at
cellular inflammation, the investigators
focused on the monocyte CD40L/CD40
dyad and showed that it was upregulated
supporting increased cellular inflamma-
tion (7). In that study, however, the inves-
tigators did not examine the signaling
pathway and the relevant biomediators.
They also used BMI and not waist circum-
ference as a criteria to define MetS. In pa-
tients with MetS with diabetes, Fortuño
et al. (22) showed increased NADPH ox-
idase activity and increased plasma levels
of both nitrotyrosine and oxidized LDL
levels, clearly supporting increased oxida-
tive stress. Also,Nakagomi et al. (23) showed
increased tissue factor procoagulant activ-
ity in patients with MetS, which correlated
with increased endotoxin levels, CRP, and
HOMA. However, it is unclear from their
reports if they excluded patients with di-
abetes and smokers because in their sec-
ond report, which showed a correlation
with carotid intima-media thickness
(24), 67% of the patients were diabetic
and 63% were smokers. Nonetheless,
their studies at the cellular level support
the posit that MetS is a procoagulant state.
Since there is such sparse data on mono-
cyte function in MetS and, in our view, it
is a high-risk obesity state, it is important
to point out that in patients with obesity,
mononuclear cell, monocyte and adipose
tissue TLRs, and other accepted biomark-
ers of inflammation have been reported.
Ghanim et al. (5) made a novel observa-
tion that in 16 obese patients compared
with control subjects, obesity was a proin-
flammatory state by showing increased
NF-kB activity and increased levels of
IL-6, TNF, migration inhibitory factor,
and matrix metalloproteinase (MMP)-9.
They also showed that the inflammatory
mediators were related to BMI. Thus, we
confirm this finding in a high-risk obesity
state and argue that MetS is a proinflam-
matory state independent of adiposity
since all our reported findings persisted
following correction for both waist cir-
cumference and BMI.
Thus, a brief summary of the pub-
lished studies support the notion that
MetS at the cellular level is a proinflam-
matory state (adipose tissue and mono-
cytes contributing), a procoagulant state,
and associated with increased oxidative
stress. A weakness of the current study is
that we provide little in the way of mech-
anistic insight for the increased TLR ac-
tivity. Potential culprits include FFA,
endotoxin, and CRP (13,25,26). We found
no significant correlation with CRP and
TLRs. However since TLR4 receptor abun-
dance correlated with both endotoxin and
FFA levels, it appears that both of these
factors could be accounting in part for the
increase in TLR4 activity. Mechanisms that
have been advanced to explain TLR2 and
TLR4 ligand recognition and receptor acti-
vation with FFA include increased reactive
oxygen species and fatty acid acylation in
Figure 3dMonocyte cytokines in MetS. Monocytes were isolated by negative magnetic sepa-
ration and incubated overnight with LPS (100 ng/mL). Cell supernatants were used for multiplex
immunoassay analyses of chemokines/cytokines and expressed per milligram cell protein as
described in RESEARCH DESIGN AND METHODS. *P , 0.05 compared with control subjects.
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lipid (essential moiety of LPS) or bacterial
lipoproteins (27). Importantly, neither en-
dotoxin nor FFA correlated significantly
with TLR2 receptor abundance suggesting
that other factors could be at play. In pa-
tients with diabetes, we have shown (15,28)
increased levels of endogenous ligands
such as high-mobility group box 1
(HMGBI), heat shock protein 60 (HSP60),
and HSP70. In future studies, we will de-
termine the contribution of these ligands
on both TLR2 and TLR4.
Since this study in its entirety exam-
ined endothelial progenitor cell biology
(14), adipose tissue dysregulation (6),
and monocyte TLR activity, we were lim-
ited by the amount of blood obtained to
undertake all analyses.
In conclusion, we make the novel ob-
servation that both of the functional recep-
tors TLR2 and TLR4 expression and activity
are increased in the monocytes of patients
with MetS and could contribute to their
increased risk for both diabetes and CVD.
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